X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment

    New Targeted Cancer Treatment Therapies Scouted By Singapore

    Ghana Gives Go Ahead To Oxford University Malaria Vaccine

    As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

    Research Pins Down New Target To Get Rid of Blood Cancer

    Customised Blood Pressure Treatment Can Get More Protection

    Customised Blood Pressure Treatment Can Get More Protection

    Novel Therapy Uses Blood Cells of Patients To Fight Tumour

    Redesigning The Human Medicines Directive And Regulation

    FDA Backs Randomized Controlled Trials For Speedy Drug Nods

    Sustained Release Chemotherapy, A Way Out For Bladder Cancer

    Cell-Energy Activity In Organs, Tissues By New MRI Method

    Cell-Energy Activity In Organs, Tissues By New MRI Method

    GE Healthcare Launches Viral Vector Based Gene Therapy Manufacturing

    Australia Sepsis Study To Aid In New Antibiotic Discovery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment

    New Targeted Cancer Treatment Therapies Scouted By Singapore

    Ghana Gives Go Ahead To Oxford University Malaria Vaccine

    As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

    Research Pins Down New Target To Get Rid of Blood Cancer

    Customised Blood Pressure Treatment Can Get More Protection

    Customised Blood Pressure Treatment Can Get More Protection

    Novel Therapy Uses Blood Cells of Patients To Fight Tumour

    Redesigning The Human Medicines Directive And Regulation

    FDA Backs Randomized Controlled Trials For Speedy Drug Nods

    Sustained Release Chemotherapy, A Way Out For Bladder Cancer

    Cell-Energy Activity In Organs, Tissues By New MRI Method

    Cell-Energy Activity In Organs, Tissues By New MRI Method

    GE Healthcare Launches Viral Vector Based Gene Therapy Manufacturing

    Australia Sepsis Study To Aid In New Antibiotic Discovery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Ghana Gives Go Ahead To Oxford University Malaria Vaccine

Content Team by Content Team
14th April 2023
in FDA Approvals, News

A malaria vaccine called R21/Matrix-M, which was developed in collaboration with the University of Oxford as well as a manufacturer of vaccines and immunological products from India, has been given the licence to be used in Ghana by the Food and Drugs Authority over there.

The vaccine, which leverages adjuvant technology from one of the leading US biotech companies in this domain, has been awarded a licence to be used across the country.

With this, it is the first clearance for R21/Matrix-M malaria for use in any specific country. It is well to note that the vaccine has been approved for use among children from 5 to 36 months, a bracket that happens to be at the highest risk of succumbing to malaria.

It happens to be a low-dose vaccine that can be manufactured at a wide scale and that too at a reasonable cost, thereby enabling millions of doses to be supplied to African countries that are already suffering from a significant malaria burden.

Moreover, it has also been demonstrated that the high levels of safety as well as efficacy have been seen in phase 2 trials even for those children who got a booster dose of R21/Matric-M at one year, which was followed by a primary three-dose regime. It is anticipated that this landmark regulatory decision will help Ghanaian and African children thwart malaria.

Adar Poonawalla, who happens to be the CEO of a leading manufacturer of vaccines and immuno-biologics from India, had no doubts about the impact this vaccine would go on to make. As per him, malaria happens to be a life-threatening disease that affects disproportionately the most susceptible populations across society, thereby being a leading cause of death among children.

He added that coming up with a vaccine to massively impact this enormous disease burden was indeed extraordinarily challenging. He added that they happen to be committed to their vision of health for all, thereby making sure of equal access to vaccines for populations across the world.

Adrian Hill, Professor and Director at the Jenner Institute at the Nuffield Department of Medicine under the gamut of the University of Oxford, said that this marks the end of 30 years of malaria vaccine research undertaken by Oxford with the provision as well as design of a high-efficacy vaccine that can get supplied at an appropriate scale across the countries that need them the most.

He also went on to congratulate the clinical trial partners in Africa who could generate the dataset that supported the safety as well as the efficiency of the vaccine among children.

John Jacobs, the president and CEO of the US biotechnology company involved in the research, said that they are thrilled that this Matrix-M adjuvant has contributed towards the success of this much-needed and promising malaria vaccine. He added that it happens to be their intent to unlock the potential of their adjuvants both in the short and long term to consistently enhance public health.

Previous Post

Research Pins Down New Target To Get Rid of Blood Cancer

Next Post

New Targeted Cancer Treatment Therapies Scouted By Singapore

Related Posts

Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment
News

New Targeted Cancer Treatment Therapies Scouted By Singapore

14th April 2023
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
News

Research Pins Down New Target To Get Rid of Blood Cancer

14th April 2023
Customised Blood Pressure Treatment Can Get More Protection
News

Customised Blood Pressure Treatment Can Get More Protection

13th April 2023
IPR Data Management

Elevating Vaccine Stability Through Predicting mRNA Degrades

13th April 2023
Silverback Therapeutics Raises $78.5 Million to Advance Cancer Antibody Conjugates for Solid Tumors
IPR Data Management

Microbial Fermentation Tech Market To Go Beyond $56b In 2023

12th April 2023
News

Novel Therapy Uses Blood Cells of Patients To Fight Tumour

12th April 2023
Next Post
Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment

New Targeted Cancer Treatment Therapies Scouted By Singapore

Latest News

Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment
News

New Targeted Cancer Treatment Therapies Scouted By Singapore

14th April 2023
FDA Approvals

Ghana Gives Go Ahead To Oxford University Malaria Vaccine

14th April 2023
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
News

Research Pins Down New Target To Get Rid of Blood Cancer

14th April 2023
Customised Blood Pressure Treatment Can Get More Protection
News

Customised Blood Pressure Treatment Can Get More Protection

13th April 2023
IPR Data Management

Elevating Vaccine Stability Through Predicting mRNA Degrades

13th April 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In